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SHORT-TERM SECOND SMOKE EXPOSURE PREDIPOSES HE LUNG 





 To determine whether cigarette smoke exposure predisposes lungs to secondary 
injury, our laboratory developed a hamster model using lipopolysaccharide (LPS) to 
induce pulmonary inflammation following exposure to second-hand smoke. With this 
model, inflammatory effects of LPS on smoke-exposed hamsters was measured by 
various morphological and biochemical parameters. Additional experiments studied the 
effects of exogenous ET-1 and BQ123, which modulate the adherence of inflammatory 
cells to lung capillary endothelium. Total bronchoalveolar lavage fluid (BALF) 
leukocytes, percent BALF neutrophils, and elastin-specific desmosine and isodesmosine 
(DID) crosslinks (free and peptide-bound) in BALF and whole lungs were measured 24 
hours (hrs) after LPS treatment. Morphometric changes were evaluated with the mean 
linear intercept (MLI) method which measures airspace enlargement, and a disease index 
was used to quantify the thickness of interstitial walls and the intensity of inflammatory 
infiltrates 24 hrs post-LPS treatment. Animals treated with smoke and LPS showed a 
significant increase in BALF neutrophils (15.0% vs 5.1%, respectively) and free lung 
DID (359 vs 93.1 ng/mg wet lung) compared to the room-air/LPS group. There was also 
a significant increase in the disease index in the smoke/LPS group compared to room 
air/LPS controls (1.6 vs 0.9 respectively).  As a measure of irreversible lung injury, MLI 
was significantly elevated in the smoke/LPS group compared to room air/LPS controls 
 
 
(83.6 vs 55.7 um, respectively).  Conversely, animals treated with BQ123 before 
smoke/LPS administration showed a significant decrease in BALF neutrophils compared 
to smoke/LPS alone (8.5% vs 15.8% respectively). While BALF neutrophils were 
significantly increased in room air-exposed animals given ET-1 compared to room air 
alone (13.9% vs 5.2%, respectively), the addition of ET-1 to animals given smoke and/or 
LPS had anti-inflammatory effects, suggesting ET-1 counteracts the proinflammatory 
activity of these other agents. The results of these studies demonstrate that the 
combination of cigarette smoke and secondary inflammation induced by LPS causes 
severe acute lung injury that degrades lung elastic fibers and enlarges airspaces. 
Treatment with BQ123 reduced this inflammatory process, suggesting it may have a 
therapeutic role in reducing the risk of lung damage in smokers with pneumonia or other 
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CHAPTER 1: INTRODUCTION 
1.1 Cigarette and Secondhand Smoke 
 According to the Center for Disease Control and the US Surgeon General, 
tobacco smoking is the leading preventable cause of death in the United States that causes 
more than 480,000 deaths each year (United States Department of Health and Human 
Services, 2014). Smoking has caused more deaths each year than HIV and illegal drug 
use. It has also been well established that smokers are more susceptible to chronic 
diseases such as periodontal diseases, hypertension, chronic obstructive pulmonary 
disease (COPD), impotence, and osteoporosis. However, smokers are more susceptible to 
bacterial infections than are non-smokers and such infections are life-threatening. Both 
active smokers and people exposed to secondhand smoke toxins are at increased risk of 
bacterial infections. Smoking continues to be a major risk factor without having COPD 
because it makes individuals susceptible to bacterial infections such as invasive 
pneumococcal disease. This disease involves any infection caused by bacteria called 
Streptococcus pneumoniae and has been shown that smoking is the strongest risk factor 
for this disease. In secondhand smoking, exposure to it has been associated with an 
increased risk of meningococcal disease and it is a significant risk factor for children 
attributed to maternal smoking. As such, cigarette smoke can rapidly induce the 
production of several inflammatory mediators that recruit inflammatory cells to the lung. 
Therefore, even short-term exposure to second-hand smoke might predispose the lung to 
secondary injury by other agents. About humans, the model provides an opportunity to 





1.2 Secondhand Smoking and Bacterial Infections 
  Tobacco smoking continues to be a prevalent long-term problem in both the 
United States and the world. A global study was created called the Global Burden of 
Diseases in which it looked at the major causes and factors of deaths across the world and 
smoking was ranked two on the major cause of deaths. The study has stated that more 
than 8 million people died prematurely because of smoking in 2017 and 7 million people 
died from smoking tobacco alone. Specifically, secondhand smoking is a concurrent issue 
as it causes large health impacts (Naghavi et al., 2017). It has been estimated 1.2 million 
people died prematurely from secondhand smoke. Since 1964, approximately 2.5 million 
nonsmokers have died from health problems caused by exposure to secondhand smoke 
(United States Department of Health and Human Services, 2014). When put in 
comparison to other causes of death secondhand smoke kills more people than road 
accidents globally. Globally, the US is one of the many countries in which smoking is 
considered a major cause of death in the nation. According to the CDC, nearly 14 of 
every 100 U.S adults aged 18 years or older currently smoke cigarettes. However, there 
has been a decline in smoking since 2005 from 21 of every 100 adults to 14 of every 100 
adults. With the decline of cigarette use, cigarette smoke-related issues continue to persist 
in those individuals and the people who are being exposed unintentionally to cigarette 
smoke. This unintentional exposure is called secondhand smoking in which the cigarette 
smoke comes from the burning end of the cigarette bud and is breathed out by the 
smokers. In recent years, there has been a decrease in the number of nonsmokers being 
exposed to secondhand smoke due to the changes in the rules for smoking in public and 




socially acceptable. It continues to be a problem as it causes numerous health problems in 
infants and children, including more frequent and severe asthma attacks, respiratory 
infections, and sudden infant death syndrome. Secondhand smoke has been known to 
cause lung cancers in adults who have never smoked, and secondhand smoke causes 
more than 7,300 lung cancer deaths among U.S non-smokers each year. Primarily, this 
laboratory is studying the effects of secondhand smoking and a bacterial infection 
stimulated by lipopolysaccharides. It is well known that smokers are more susceptible to 
nonsmokers to a wide range of chronic diseases. However, smokers become more 
susceptible to multiple bacterial infections than nonsmokers and such infections can be 
dangerous.  
There are many bacterial infections associated with tobacco smoking such as 
nasopharyngeal, respiratory tract infections, bronchitis, and COPD (Bagaitkar et al., 
2008). There are potential mechanisms on why there is an increased susceptibility to 
bacterial infections such as tobacco-induced physiological and structural changes in 
humans, increase in bacterial virulence, and the dysregulation of the immune function. 
These mechanisms are not mutually exclusive, and they can all occur simultaneously 
(Bagaitkar et al., 2008). There have been instances where tobacco smoke exposure may 
play a direct role in bacterial colonization of the respiratory tract by hindering the 
clearance of bacteria. Cigarette smoke may also have physiological and structural 
changes in vasculature and respiratory tract such as inducing vasoconstriction of the 
peripheral arteries but vasodilation of the cerebral blood vessels.  
 




Pulmonary emphysema is a progressive lung disease that is a categorized form of 
COPD. It is often caused by chronic and significant exposure to noxious gases and most 
commonly caused by cigarette smoking. There are also possible causes for emphysema 
such as biomass fuels and environmental pollutants such as sulfur dioxide and particulate 
matter (Pahal P, Avula A, 2020). The manifestations of emphysema are the consequences 
of damage to the airways and bronchioles which includes alveolar sacs and the alveoli. 
The damage causes abnormal permanent dilation of the airspaces and the destruction of 
the alveoli walls due to the proteinases such as elastase (Pahal P, Avula A, 2020). As 
elastin is an important component of the extracellular matrix that is required to maintain 
the lung parenchyma and small airways, the elastase and anti-elastase imbalances 
increase the susceptibility for the lung to be damaged which can lead to airspace 
enlargement (Pahal P, Avula A, 2020). This allows to conduct a method called mean 
linear intercept on the lung airspace diameter as cigarette smoking and secondhand 
smoking can increase your risk of emphysema and COPD (Thurlbeck, 1967). The 
measurement of the lung airspace will help us determine whether the combination of 
secondhand smoke and a bacterial infection can cause enlarged airspace in the lung. 
 
1.4 Neutrophils and Cigarette Smoke 
 Neutrophils are the main concern in this experimental model as it is one of the 
most abundant types of white blood cells and forms the essential part of the innate 
immune system. This becomes important as cigarette smoking has been strongly 
associated with multiple respiratory infections such as Streptococcus pneumoniae and 




2019). Neutrophils are an important biomarker as they are the most abundant leukocyte in 
the human body and are considered the first line of defense in the innate immune system. 
They can destroy invading foreign bodies through phagocytosis and intracellular 
degradation. They are also considered mediators of inflammation. These infections and 
diseases are often the major cause of mortality across the world. The influx of pulmonary 
neutrophils often occurs in response to bacterial infection and a common feature of 
chronic inflammatory lung diseases. A theory has been proposed by the American 
Thoracic Society that compromised anti-bacterial nature in neutrophils may be a major 
cause of increased susceptibility to infectious diseases in smokers (Guzik et al., 2011).  
 
1.5 Lipopolysaccharides 
 Lipopolysaccharide (LPS) is the major component of the outer membrane of 
Gram-negative bacteria. Lipopolysaccharide is localized in the outer layer of the 
membrane and is exposed to the cell surface. The general structure of LPS is a 
hydrophobic lipid section that is responsible for the toxic properties, a hydrophilic core 
polysaccharide chain, and a repeating hydrophilic O-antigenic oligosaccharide side chain 
that is specific to the bacterial serotype. The LPS used in the studies is from Escherichia 
coli O26:B6 (L8274) sourced from Sigma-Aldrich. The function of LPS is to protect the 
bacterium against the action of bile salts and lipophilic antibiotics. LPS are heat-stable 
endotoxins and have been recognized as a factor in septic shock in humans and more 
generally for inducing a strong immune response in normal mammalian cells. LPS has 
been widely used for lung inflammation models to simulate chronic lung diseases such as 




occurs. In our study, LPS is being used to simulate a condition of a secondary lung 
infection after a chronic smoker contract a respiratory disease or infection. This is due to 
the fact smoking is a factor in increasing the risk for respiratory infections and 
exacerbating chronic lung diseases.  
 
1.6 Endothelin-1 and Cigarette Smoke 
 Endothelin or ET is a family of 21 amino acid peptides that have a wide range and 
overlapping functions in the lung and its associated diseases. There are three different 
isoforms of endothelin, ET-1, ET-2, and ET-3. ET-1 is one of the most abundant isoforms 
and better chartered and the only difference between the three is the number of amino 
acids in each one. The lung has the highest levels of ET-1 secreted by endothelium, 
smooth muscle, airway epithelium, and a variety of other cells. ET-1 circulates in the 
plasma and the normal lung, it localizes to the vascular endothelin, airway, and vascular 
smooth muscle cells. There is less ET-1 in the lung epithelium. ET-1 has been implicated 
in a long list of lung diseases such as ischemia pulmonary edema, acute respiratory 
distress syndrome, sepsis, asthma, chronic obstructive pulmonary disease, pulmonary 
fibrosis. ET-1 is not stored in cells, but it is processed and transported through the cell in 
vesicles which results in direction secretion toward the smooth muscle, and it allows for 
ET-1 to act in a paracrine or autocrine manner. This secretion into the circulation allows 
for the ET-1 to act as a hormone (Kowalczyk et al., 2015). 
 There are currently two distinct human endothelin receptors called endothelin A 
(ETA) and endothelin B (ETB) receptors. ETA specifically has a higher affinity for ET-1 




smooth muscle of the lung. ETB is found mostly on the lung endothelium and the 
clearance of ET-1 is mediated by the ETB receptor primarily in the lung but also in the 
kidney and liver. The activation of both receptors causes the ETA on the smooth muscle 
cells to constrict while the ETB causes bronchoconstriction (Kowalczyk et al., 2015). 
 Endothelin-1 is the focus of our experiments as it is an important biomarker for 
lung injury and inflammation. Since ET-1 is produced in large amounts in the 
endothelium, there are often large amounts of it in the bronchoalveolar lavage fluid and 
indicates that there is inflammation or some sort of injury in the lungs. Experimental lung 
injury of many different types increases circulating ET-1, BAL ET-1, and lung tissue ET-
1. These levels are also increased in cases of sepsis, burns, acute lung injury, and acute 
respiratory distress syndrome (Kowalczyk et al., 2015).  
 
1.7 Endothelin Antagonists and BQ-123 
 Since the endothelin family has powerful vasoconstrictor properties, it has been 
implicated in the pathogenesis of pulmonary diseases and COPD. These studies allow for 
the introduction of endothelin receptor antagonists. Endothelin receptor antagonists are a 
type of target therapy used to treat people with pulmonary hypertension and have been 
shown to slow the progression of pulmonary hypertension and may reverse some of the 
damage to the heart and lungs. This is done by reducing the amount of endothelin in the 
blood which would limit the harm of excess endothelin in the body. There are several 
different types of antagonists such as BQ-123, FR 139317, TAK-044, and BQ788. Our 
focus on our experiments is the use of the cyclic pentapeptide BQ-123. The structure of 




misakiensis (Ihara et al., 1991). The role of BQ-123 is that it is a potent and selective 
antagonist for ETA and it also inhibits ET-1 receptor binding and blocks Ca2+ 
mobilization, cellular contraction, and MAP kinase activation. The inhibition of ET-1 and 
ETA-R using BQ-123 is done by reversing the established contractions to the receptor, 
displacing the peptide from it. It has been studied for potential therapeutic effects in 
preventative lung injury such as emphysema and COPD (Chen et al., 2010). It can also be 
a viable treatment for such diseases, and it may be possible to be used in the treatment of 
other chronic diseases such as pulmonary hypertension (Hanasato et al., 1999). 
 
 1.8 Desmosine and Isodesmosine 
Elastin cross-linking in the lung consists of two amino acids unique to mature 
elastin; desmosine and its isomer isodesmosine (DID) which can be used as a biomarker 
of smoked induced emphysema and COPD (Luisetti et al., 2008). Specifically, free 
desmosine has been used as a measure for smoke-induced damage and COPD. 
Desmosine in several matrices such as urine, plasma, and sputum have been used to 
determine whether patients have COPD or emphysema (Ma et al., 2011). Liu et al. 
reported an increased level of free DID when hamsters were exposed to secondhand 
cigarette smoke for 2h/day, 5 days/week for a period of 3 months (Liu et al., 2015). 
Another study by Churg et al showed a consistent increase in desmosine and 
hydroxyproline, both degradation products of the extracellular matrix, in BALF of 
smoke-exposed animals after 6 and 24 hours (Wright et al., 2002).  
Improvements have followed when it comes to measuring desmosine such as the 




spectrometry. Generally, the measurement of desmosine is designed for total desmosine 
amounts and requires hydrolysis of plasma and urine samples in concentrated HCl to 
unbind the biomarkers. Instead, the use of a deuterium labeled internal standard was 
added directly to a matrix sample which allows for improved accurate and precise 
reading of the free desmosine levels (Miliotis et al., 2013).  
 
1.9 Experimental Design 
Our laboratory has created an animal model designed to look at the relationship 
between acute exposure to cigarette smoke and secondary lung injury induced by 
injecting lipopolysaccharide (LPS) intraperitoneally into hamsters. This is done by using 
a TE-10 smoking machine which exposes the hamsters to secondhand cigarette smoke.  
The inflammation induced by LPS mimics bacterial pneumonia, which is often worse in 
cigarette smokers due to increased sequestration of inflammatory cells in the lung 
vascular compartment. The cigarette smoke will expose hamsters to a 3-day regimen of 
second-hand smoke inhalation to determine if this procedure is sufficient to recruit 
inflammatory cells to the lung, the hamster will be injected intraperitoneally with 0.1ml 
of 0.2mg/ml of LPS. In addition to LPS, other agents are being tested which include 
BQ123 and exogenous endothelin-1. Exogenous endothelin-1 has been used in our 
laboratory which has proven to modulate the adherence of inflammatory cells to 
endothelium in the lung capillary network (T. Bhavsar et al., 2008). If BQ123, an FDA-
approved drug, is found to inhibit inflammatory cell influx, it may serve as a potential 




Using this model, we will test our primary hypothesis that short-term exposure to 
cigarette smoke predisposes the lung to secondary injury by increasing the inflammatory 
response to LPS. Parameters that will be evaluated include histopathological changes in 
the lung, cell content in bronchoalveolar lavage fluid (BALF), and the amount of free and 
peptide-bound desmosine in BALF. In addition, the effect of LPS on BALF leukocyte 
chemotaxis will be tested in vitro. 
Our laboratory has previously tested the use of endothelin-1 which caused 
preferential recruitment of neutrophils in acute lung inflammation induced by either LPS 
or cigarette smoke (T. Bhavsar et al., 2008). When ET-1 was injected into the smoked-
exposed animals, it caused an increased number of neutrophils in the BALF but a reduced 
total number of BALF leukocytes. In our experiment, we hypothesize that injection of 
ET-1 increases the neutrophil response in the lung to the combination of both cigarette 
smoke and LPS.  
Our laboratory has also tested drugs in dealing with inflammation of the lungs, 
secondary infections, and possible treatments in COPD. Certain substances such as 
phosphoramidon and HJP272 have been tested as viable drugs to block the formation of 
inflammatory mediators such as endothelin-1 (Patel et al., 2014). Phosphoramidon is a 
known zinc metalloproteinase inhibitor that blocks the formation of ET-1 and it has 
shown to be a valuable tool in the study of hypertension, stroke, and diseases of the 
kidney (T. M. Bhavsar et al., 2008). It has shown to cause a reduction of acute 
inflammation in the LPS-induced lung injury. In our experiments, we tested the viability 
of BQ-123 as another drug in the treatment of LPS-induced lung injury. It is a known 




emphysema in rats. BQ-123 has been proven to prevent the development of cigarette 
smoke extract-induced emphysema, block the expression of ETA receptors, and inhibit 
pulmonary apoptosis. In our experiments, we hypothesize that BQ-123 can block 
endothelin-1 activity to decrease the neutrophil response toward cigarette smoke or the 
combination of cigarette smoke and LPS.  
To test these hypotheses, hamsters will be exposed to cigarette smoke for 3 days, 
and then treated with lipopolysaccharide (LPS) to induce secondary lung injury. It is 
anticipated that animals exposed to smoke will have a significantly greater reaction to 
LPS than those treated with LPS alone. The relationship between brief (second-hand) 
cigarette smoke exposure and lung injury remains unclear. We have studied the effect of 
lipopolysaccharide (a proinflammatory mediator present in tobacco) on this process to 
determine this relationship. Other agents to be tested include BQ123 and endothelin-1, 
which both drugs can modulate the adherence of inflammatory cells to endothelium in the 
lung capillary network. If BQ123, an FDA-approved drug, is found to inhibit 
inflammatory cell influx, it may serve as a potential therapeutic agent for the prevention 
of lung injury due to cigarette smoke. 
 The first experiment that has been performed was the pilot study on the viability 
of intraperitoneal injection of LPS after the hamsters were exposed to cigarette smoke for 
2 hours in a period of 3 days. The concentration of the LPS injected into the hamsters 
would be 0.2mg in 0.1 ml of saline. This is done to affirm that IP injection of LPS can 
simulate the bacterial infection of the lungs after the hamsters were exposed to cigarette 




hamsters. The purpose of this experiment is to show that short-term exposure to cigarette 
smoke can cause inflammation and simulate a bacterial infection in the lungs. 
 In the second set of experiments, the smoke exposure will be increased to 4 hours 
for 3 days from 2 hours. The pilot study allowed us to establish that short-term exposure 
caused some inflammation in the lungs. In this experiment, we would look at the 
possibility of increasing the exposure time to elicit more inflammation in the lungs and 
see if the LPS will cause a higher response. 
 In the third set of experiments, we added another compound called BQ-123. BQ-
123 has been proven to be a useful therapeutic agent against inflammation and lung 
injury. It can then be tested against cigarette smoke and LPS to see whether it will reduce 
the amount of inflammation occurring in the lungs and decrease the number of 
leukocytes. The dose of the BQ-123 is 200 ug in 0.1ml of saline. The smoking protocol 
has stayed the same to keep the consistency in the previous experiment. 
 In the fourth set of experiments, ET-1 was used exclusively and no LPS nor BQ-
123 was used in this experiment. Since ET-1 is a powerful vasoconstrictor, a low dose of 
5ug in 0.1 ml of saline is required for this experiment. The rationale of this experiment is 
to see whether ET-1 will cause an increase or decrease in inflammation after the hamsters 
were exposed to cigarette smoke. 
 In the fifth set of experiments, ET-1 and BQ-123 were used in this experiment. 
These two drugs will be combined with LPS to gauge the inflammatory response. This 
would determine whether BQ-123 or ET-1 can decrease the number of leukocytes or 




group to determine whether these drugs affect the thickness of the interstitium in the 
lungs and if these drugs can decrease the thickness.  
 
1.10 Possible Outcomes from Experiments 
 There are possible outcomes that can be found in these experiments. An outcome 
is that the exposure protocol may be too short to cause any major inflammation or 
damage to the lung and may not affect them as much as we think. Another outcome is 
that the short exposure to cigarette smoke and the addition of LPS may have an increased 
effect of inflammation in the lungs and cause slight thickening in the interstitial walls.  
 In the experiment using BQ-123, the introduction of an antagonist may probably 
decrease or increase the immune response towards the LPs and the Cigarette smoke. It is 
also possible that the BQ-123 will not affect the immune response as this type of 
experiment is not a well-studied treatment method, specifically in the lung. 
In experiments including the use of ET-1 and LPS, we might see an increase of 
leukocytes and inflammation in the lungs as it is well-known ET-1 is an important 
indicator for lung injury in the BALF and as “free ET-1”. Although due to ET-1 being a 
powerful vasoconstrictor, it may decrease the number of leukocytes entering the lung to 
respond to LPS and cigarette smoke.  
 
1.11 Summation 
The effects of acute secondhand smoking and bacterial infections are still unclear. 
This model will allow us to observe the effects and allow us to determine the relationship 




our laboratory has created a hamster model that allows us to replicate secondhand 
smoking using a smoking machine and injecting LPS to cause a bacterial infection in the 
lungs. Compared to previous models, we will be using a minimum amount of LPS and 
using other agents to look for therapeutic agents to provide an alternative treatment to 
secondhand smoke inhalation and bacterial infections  
 
1.12 Objectives, Hypothesis, Specific Aims 
1.12.1 Objectives 
 From these discussions, the effects of acute cigarette exposure and its damage to 
the lungs are not well studied.  The discussion that usually occurs when it comes to 
smoking tobacco products is usually for chronic damage that occurs in long-term smokers 
and those who are exposed to secondhand smoke for a long period. With these studies, 
we can look at whether short periods of secondhand smoking can predispose the lung to 
secondary injury. 
The objective of this study was to explore the effects of short-term secondhand 
smoke exposure and the immune response from LPS treatment. This study also looks at a 
possible treatment involving an endothelin receptor antagonist, BQ123.  
1.12.2 Hypotheses 
- Second-hand smoke can cause short-term inflammation and can enhance 
secondary injury caused by LPS. 
- The combination of smoke and LPS may cause damage to lung elastic fibers, 
resulting in airspace enlargement. 




- The addition of ET-1 may increase the secondary inflammatory activity of LPS. 
1.12.3 Specific aims 
- To examine the effects of short-term, secondhand cigarette smoke and the effects 
of a simulated bacterial infection via LPS in a hamster model on various factors of 
inflammation such as lung histology, BAL neutrophils, desmosine levels, and 
neutrophil chemotaxis 
- To observe the effects of BQ-123 on LPS and cigarette smoke as a possible 
treatment for smoke-related secondary lung injury 
- To evaluate the effects of exogenous ET-1 on lung inflammation induced by 
cigarette smoke and LPS. 
Aim 1: To test the first hypothesis, we needed to determine the effects of short-term 
secondhand cigarette smoke on LPS-induced infiltration of inflammatory cells into the 
lungs, the damage on the lung parenchymal, and the elastic fiber injury. These were 
evaluated by the following parameters. 
a)   Total leukocyte count in BALF 
b)   Percent neutrophil count in BALF 
c)   Total and free DID content in BALF 
d)   Average Thickness of interstitial walls 
Rationale: The number of leukocytes and neutrophils in the BALF following the 
treatment of LPS and secondhand cigarette smoke demonstrates the extent of 
inflammation in the lungs that would help us understand the effects of a bacterial 




interstitial walls in the lung can help us understand the damage caused by both the 
cigarette smoke and the LPS. This may help explain the deterioration of lung function 
when two inflammatory agents are present in the lung.  
Aim 2: To test the second hypothesis, the procedures for the smoke inhalations and 
injections are the same. However, we added an additional substance to test the efficacy of 
a possible treatment for the damage caused by both the bacterial infection and the 
cigarette smoke called BQ-123. It has been used previously in a study to find the efficacy 
of inhibiting cigarette smoke-induced endothelin receptor expression in pulmonary 
arteries. These were evaluated by the following parameters. 
a)   Total leukocyte count in BALF 
b)   Percent neutrophil count in BALF 
c)   Total and free DID content in BALF 
Rationale: The reason for this experiment is to find treatments for cigarette-induced 
bacterial infections as smoking increases your risks of bacterial infections such as 
tuberculosis and pneumonia. By testing a substance with known properties of decreasing 
the damage of cigarette smoke and bacterial infections, we may be able to provide 
evidence that BQ-123 can be an effective treatment for such issues.  
Aim 3: To test this hypothesis, the procedure for the smoke inhalation is the same but the 
procedure for the injections is different. We introduced a standalone substance called 
endothelin-1 or ET-1 This will be used to determine whether the introduction of an 
inflammatory mediator will increase the recruitment of leukocytes into the lung after 




Rationale: The reason for such a treatment is that the lab has previously experimented 
with ET-1 to demonstrate that the introduction of ET-1 can causes preferential 
recruitment of neutrophils. In this experiment, we want to determine whether the 
introduction can reduce the inflammation and recruitment of neutrophils after being 






















Chapter 2: Materials and Methods 
2.1 Materials and Methods 
2.1.1 Cigarette Source 
 The cigarettes were provided by the Center for Tobacco Reference Products 
(CTRP), part of the University of Kentucky, College of Agriculture. The specific 
cigarette we used is the 3R4F. The 3R4F Kentucky reference cigarettes have been widely 
used as monitor cigarettes for mainstream smoke analysis and in vitro and in vivo 
toxicological data of cigarettes and novel tobacco products. The 3R4F product is then 
shipped to the CTRP where the cases are placed in plastic bags and stored in a cold room 
at approximately 3.3°C and 50-60% relative humidity. This type of cigarette is the ideal 
product for the experimental model and has been used in different experiments such as 
studies for COPD and secondhand smoking.  
 These cigarettes will be used in the TE-10 Teague Enterprises smoke machine. It 
is a microprocessor-controlled cigarette smoking machine that produces either side-
stream or mainstream smoke or a combination of the two from filtered, non-filtered, or 
standard size research cigarettes. One to ten cigarettes can be smoked at a time. 
Cigarettes are loaded into a magazine where they are automatically pushed into a wheel 
and lighted. The cigarettes are puffed according to the FTC method and automatically 
ejected after a certain number of puffs. Expended butts are extinguished in water. Smoke 
is captured in a chimney and transported to a collecting and mixing chamber for use in 
exposure studies. The size of the smoking chamber that the animals will be contained is 




The average total smoke particulates are measured using an AME Volumetric dry 
gas meter combined with a timed filter sampler which has a diaphragm pump and a timer. 
The air mover is a linear pump with a maximum sample flow rate of 17 LPM. The 
outflow from the pump can be connected to a dry gas meter to measure volume sampled. 
A 0.45um EMD Millipore filter paper was used to weigh the smoke particles. The filter 
paper is first weighed before it is inserted into the in-line filter holder and the meter 
number is read before it is activated to vacuum the smoke into the filter paper. After 4 
hours, turn off the meter, read the measurement on the meter, and remove the filter and 
weight the filter. To calculate the smoke particulate matter, take the difference of the 
gravimetric measurements before and after it is read and the weight of the filter paper 
before. Then divide the difference of the paper weight by the gravimetric difference. This 
is expressed in mg/m3. The average total smoke particulates were 15.7mg/m3 at a SEM of 
5.6.  
2.1.2 Animals 
 Female Golden Syrian hamsters, weighing 90-100 grams, were purchased from 
Envigo. (Somerset, NJ) were used throughout the study. 2-3 animals were housed per 
cage with food and water available ad-libitum for at least 24 hours before any 
experimentation. All protocols were approved by St. John’s University Institutional 
Animal Care and Use Committee.  
 
2.2 Experimental Design 




 A preliminary experiment was conducted to check the efficacy of performing an 
intraperitoneal injection of LPS to induce inflammation in the lungs. The smoking 
procedure is exposing the animals to secondhand cigarette smoke for 2 hours per day for 
a period of 3 days. The animals were then injected with 200ug of LPS in 0.1ml saline and 
left to rest for 24 hours. They were then euthanized via CO2 asphyxiation.  
2.2.2 Model 1 - LPS 
 In the first experiment, the smoking duration was increased from 2 hours to 4 
hours to simulate the effects of acute secondhand smoke. The animals were divided into 
two groups, Group 1 was exposed to the smoke chamber and Group 2 was exposed to the 
room air in the Animal Care Center. After being exposed to the smoke and left to rest for 
24 hours, all the groups will be injected with 200ug of LPS in 0.1ml NaCl solution and 
left to rest. They were then euthanized after 24 hours via CO2 asphyxiation.  
2.2.3 Model 2 - BQ-123 
In the second experiment, the smoking protocol remained the same, but the 
injection protocols were modified. We decided to test the efficacy of an antagonist called 
BQ-123 to look at it as a possible treatment for smoke-induced emphysema. Group 1 was 
exposed to cigarette smoke while group 2 was exposed to room air. After they were 
exposed and were left to rest for 24 hours, Group 1 was injected with 200ug of BQ-123 in 
0.1ml of saline. The animals were left to rest for 30 minutes and then all groups were 
injected again with LPS. They were then euthanized after 24 hours via CO2 asphyxiation. 
2.2.4 Model 3 - ET-1 
In the third experiment involving ET-1, four groups were created: Group 1 was 




smoke and injected with ET-1, and group 4 was exposed to room air and injected with 
ET-1. The dose of ET-1 will be 10ug in 0.1ml of saline. They will then be euthanized 
after 24 hours via CO2 asphyxiation. 
2.2.5 Model 4 – BQ-123, ET-1, and LPS 
 In the fourth experiment, it involves the use of all three substances. Four groups 
were created: Group 1 were exposed to cigarette smoke, injected with BQ123, and then 
injected with LPS 30 minutes later; Group 2 were exposed to cigarette smoke, injected 
with LPS, and then injected with ET-1 30 minutes later; Group 3 were exposed to 
cigarette smoke and injected with LPS; Group 4 were exposed to room air and injected 
with PBS. They were all euthanized after 24 hours via CO2 asphyxiation. 
 A total of 120 animals were used in both sets of experiments. All procedures 
involved in these studies were reviewed and approved by the IACUC at St. John’s 
University. 
 
2.3 Extraction of Bronchoalveolar Lavage Fluid and Lung Samples 
All animals used in this study were euthanized by CO2 asphyxiation. The lower 
thoracic area of the animals was cleansed with 70% alcohol and surgically exposed to cut 
the diaphragm, ensuring complete lung collapse. An incision was made in the cervical 
area and two muscle layers (cleidomastoideus and digastricus) were cut to expose the 
trachea. A 16-gauge needle was inserted into the trachea (BD Precision Glide Needle) 
attached to a 5ml syringe. BALF was obtained by injecting and withdrawing phosphate-
buffered saline (PBS) 3 times at 4ml, 3ml, and 3ml volumes to reach a final amount of 




neutrophils from the suction of the syringe. After lavage, lungs were removed from the 
chest and separated from extrapulmonary structures, then stored at -20 degrees Celsius 
for further studies. BALF photomicrographs were taken using a Nikon Eclipse Ts2R 
inverted research microscope at a magnification of 200x. The software used to take the 
photos is a NIS-Elements Viewer.  
2.4 Microscopic Studies 
2.4.1 Histological Evaluation of the Lungs 
After euthanasia, the lungs were fixed using 10% neutral-buffered formalin for 2 
hours at a pressure of 20 cm of mercury, then removed from the chest and immersed in a 
centrifugal tube filled with formalin for 48 hours. The extrapulmonary structures were 
removed from the lungs and the samples were cut into random pieces and placed in 
cassettes for histological processing. The process of creating the blocks is done by using 
an STP 120 from Thermo Fisher. The machine is programmed to create the blocks by 
dipping them in solvents and preservatives. The cassettes were passed through graded 
concentrations of ethanol, ranging from 35%, 70%, 95%, and 100%, for 5-minute 
intervals, followed by repeated immersion in clean 100% xylene for 15, 25, and 40 
minutes. The samples were then sequentially incubated in xylene-paraffin mixture (1:1) 
for 1 hour, 100% paraffin for 1 hour, and fresh 100% paraffin for 2 hours. They were 
then embedded in blocks of paraffin wax, using a Leica 1160 tissue-embedding machine. 
The resulting tissue blocks were stored in a refrigerator before processing with a 
microtome. Tissue sections were cut with a standard rotary microtome (American Optical 




placed carefully on a SilaneTM coated slides, and incubated at 55 degrees Celsius 
overnight for future analysis.  
2.4.2 Hematoxylin and Eosin Staining (H&E) 
After the tissue sections were dried of all moisture, they were taken for staining. 
The tissue sections were deparaffinized in three changes of xylene for 5 minutes in each 
staining jar, then they were rehydrated in decreasing concentrations of ethanol (ETOH) 
from 100%, 95%, 70%, and 30% at 2-minute intervals. The sections were then washed in 
distilled water for 1 minute and stained with hematoxylin for 10 minutes. They were then 
immersed in distilled water for 2 minutes, then in a solution mixture of ammonium 
chloride (NH4CL) and ETOH for 1 minute, washed in tap and distilled water for 1 minute 
each, and dehydrated in 70% ETOH for 2 minutes. The sections were then counterstained 
in eosin solution for 2 minutes and then dehydrated in alcohol as follows: 95% ETOH for 
2 minutes and 3 changes of 100% ETOH for 2 minutes each. Finally, sections were 
cleared in 3 changes of xylene 2 minutes each mounting with coverslips using Permount. 
 Following euthanasia, the lungs were fixed in situ for several hours with 10% 
neutral-buffered formalin at a pressure of 20cm H2O. The lungs were removed from the 
thorax as a single block and fixed in formalin. After removing the extrapulmonary 
structures, the lungs were cut into random pieces and processed for histological studies. 
The solvents used are xylene, ethanol, formaldehyde, and paraffin. The blocks are then 
filled with paraffin after the tissue processor has completed its run. Slide sections were 
cut at 0.5um using an American Optical Company Microtome with Accublade microtome 
blades. The sections are then placed on a hot water bath and taken in by a SilaneTM-




from the slides. After the slides are dry, the sections are stained in hematoxylin and eosin. 
The thickness of the interstitial walls was determined by a score from 1-5. Tissue sections 
were graded for injury (inflammatory index), using the following scale based on 
previously published criteria: 0 = no reaction in alveolar walls; 1 = diffuse reaction in 
alveolar walls, with no thickening of the interstitium; 2 = diffuse presence of 
inflammatory cells in alveolar walls with a slight thickening of the interstitium; 3 = 
moderate interstitial thickening accompanied by inflammatory cell infiltrates; 4 = 
interstitial thickening involving more than half of the microscopic field. Results were 
expressed as an average of 25 microscopic fields. This type of scoring has been used 
previously to evaluate the interstitial damage to the lung and observe inflammatory cell 
infiltrates (Patel et al., 2014). The purpose of such analysis is that exposure to cigarette 
smoke and intraperitoneal injection of LPS can increase the thickness of the interstitial 
walls and the accumulation of various leukocytes. 
2.4.3 Mean Linear Intercept of the Lung Airspace Diameter 
 Another measurement was conducted on the lung sections by doing the mean 
linear intercept of the lung airspace diameters. This was done using ImageJ in which 
horizontal lines were displayed across each lung section image. For each line, the points 
where the line intersects with an alveolar wall are counted, skipping every other line for a 
total of 4 lines per image. After they are counted, divide the measured length of the image 
by the average numbers of intersecting points per line. This will give the average distance 
between the alveolar walls. The pictures were taken and measured at a magnification of 




combination of second-hand smoke exposure and secondary inflammation in the lung can 
cause enlargement of the lung airspace.  
 
2.5 Analysis of BALF 
Total leukocyte counts were determined using a hemocytometer (Hausser 
Scientific, Horsham, PA) at a magnification of 400x. The BALF was then centrifuged for 
3 minutes at 5 shelves, the supernatant was removed and stored at -20 degrees Celsius for 
further analysis. Differential cell counts were performed by resuspension of the pellet in 
1ml PBS, followed by plating of the cells onto microscope slides with a cytospin 
(Shandon Inc., Pittsburgh, USA) for 7 minutes at a speed of 800 rpm. The slides were air-
dried, fixed in methanol for 2 minutes, treated with Giemsa-Wright stain at a ratio of 3:2, 
and a coverslip was added using Cytoseal. At least 200 cells were identified using 
standard morphological criteria to determine percent neutrophil in BALF. 
 
2.6 Measurement of BALF Isodesmosine and Desmosine 
 For measurement of free DID, aliquots of cell-free lavage fluid were concentrated 
by evaporation to a volume of 0.5ml and combined with 10% trifluoroacetic acid to 
precipitate proteins, which were discarded after centrifugation. The supernatants were 
mixed with a solution of butanol, glacial acetic acid, and water (4:1:1), then applied to a 
CF1 column to separate the free DID. 
 To determine total DID, aliquots of cell-free lavage fluid were mixed with 37% 
HCl and hydrolyzed at 110°C for 24 hours. The samples were then dried, suspended in 





 Separation of the crosslinks was performed on a 2x100mm dC18 column (waters 
Corporation, Milford, MA) using 2 mobile phases: (A) 7mM heptafluorobutyric acid 
(HFBA) and 5mM ammonium acetate in 80% acetonitrile. Following elution with a 
programmed gradient, the crosslinks were analyzed with a TSQ discovery electrospray 
tandem mass spectrometer (Thermo Fisher Scientific, Waltham, MA), using selected 
reaction monitoring of mass to charge ratio transitions. A d4-labeled desmosine standard 
was used to quantify the results. 
 Another method, utilizing LC-MS-MS, was also used to determine free desmosine 
in BALF and whole lungs. The lungs were first weighed and added with an appropriate 
volume of ultra-pure water to produce a 1:2 dilution (e.g., 2 mL of water to 2 g of the 
lung). The samples were then homogenized using a Brinkmann Homogenizer. 1 mL of 
the resultant homogenate was directly aliquoted into a separate tube and fortified with 
desmosine-D4. 1 mL of BALF samples were directly aliquoted and fortified with 
desmosine-D4. 
Both desmosine and desmosine-D4 were extracted from lung and BALF samples 
by cationic exchange solid phase extraction (SPE). The cation exchange sorbent serves to 
retain desmosine and desmosine-D4. First, 3 mL of 0.1N HCl (pH ~ 1.0) was added to 1 
mL BALF or 1 mL of lung homogenate, followed by a vortex and centrifugation for 10 
min at 3000 rpm prior to column loading. The SPE cartridges were conditioned with 4 
mL of methanol followed by 3 mL of 0.1N HCl. Subsequently, the samples (3 mL of the 
pre-added 0.1N HCl and 1 mL of BALF or lung homogenate containing desmosine and 
desmosine-D4) were loaded into each designated pre-conditioned column and were 




in the order of 3 mL of 0.1N HCl and 4 mL of methanol. The columns were then allowed 
to dry at full vacuum for 30 seconds. Elution of desmosine and desmosine-D4 was 
utilized with 3 mL of a solvent prepared fresh as a mixture of 95% methanol and 5% 
concentrated ammonium hydroxide. Eluents were evaporated to dryness under vacuum 
using a Rotovap, and the residues were reconstituted in 200 μL of a 95:5 mixture of water 
and methanol and injected into the chromatographic system. 
 
2.7 Chemotaxis Assay  
BALF leukocytes from untreated animals were centrifuged and suspended in 
Dulbecco’s culture medium. They were gently mixed to ensure uniformity and placed in 
the upper wells of Boyden chambers with a 3 µm pore size membrane (Sigma-Aldrich, St 
Louis, MO) and exposed to either LPS or no LPS. The lower wells were filled with 
additional media to cover the base of the upper wells. The same volume of media was 
used for each well. Additional chambers only contained culture medium in both upper 
and lower wells and were used for background measurements. Following incubation at 37 
degrees Celsius for 24 hours, the cells were carefully removed from the top side of the 
insert. The contents of the lower wells were gently mixed to evenly distribute the cells. 
Cell migration through the membrane was determined with a CyQuant® cell assay kit 
(Thermo Fisher, Waltham, MA) which uses a fluorescent dye that binds to DNA. The 
treated cells were transferred to a 96-well microplate and a combination of fluorescent 
dye solution and lysis buffer was added to each well. The samples were incubated at 
room temperature for 15 minutes and fluorescence emission was measured with a 





2.8 Statistical Analysis 
One-way analysis of variance (ANOVA) and Bonferroni post-hoc tests were used 
to determine statistically significant differences among three or more treatment groups. 
When only two groups were compared, a two-tailed t-test was utilized.  A p-value of less 
than 0.05 was considered statistically significant. Results were expressed as mean ± 




















CHAPTER 3: RESULTS 
3.1 Model 1 – The effect of smoke on LPS-induced Inflammation 
 Syrian Golden hamsters were exposed to cigarette smoke for 4 hours per day over 
a 3-day period, then given IP LPS 24 hours later. Bronchoalveolar lavage was performed 
24 hours after LPS administration. As shown in Figure 1, animals treated with smoke and 
LPS showed a significant increase in percent BALF neutrophils compared to those given 
LPS alone (15.0 vs 5.1 percent, respectively, p<0.01). In contrast, the total BALF 
leukocytes did not show a significant difference between the groups (Figure 2). As shown 
in Figure 3, animals treated with LPS and smoke had a significantly higher disease index 
and showed thicker interstitial walls and more intense neutrophil infiltrates compared to 
LPS alone (1.6 vs 0.9, respectively; p<0.05).  
 BALF DID was also measured 24 hrs after LPS administration. The amount of 
free and total BALF desmosine was not significantly greater in the animals treated with 
both smoke and LPS compared to those given LPS alone (Fig. 5, Fig. 6).  Furthermore, 
there was no correlation between percent neutrophils and either total or free BALF 
desmosine (Figures 8 and 9). However, as shown in Figure 7, there was a significant 
correlation between free BALF desmosine and total BALF desmosine, indicating that 
free BALF DID responds to inflammatory injury in the same manner as total BALD DID, 






Figure 1. Percent BALF Neutrophils Content in Smoked Only Hamsters. Graph 
showing the percent BALF neutrophil content. The animals were treated with either 
smoke or room air, then given IP LPS 24 hours later and euthanized 24 hours after LPS 
treatment.  The group receiving smoke + LPS had significantly increased BALF 
neutrophils compare to the other groups (one-way ANOVA with Bonferroni post-test).  
The results were expressed as mean ± SEM (p=0.0003). The numbers under each bar 














Figure 2. Total BALF Leukocyte Count in Smoked Only Animals. Graph showing the 
total BALF leukocyte counts. The animals were treated with either smoke or room air, 
then given IP LPS 24 hours later and euthanized one day later. There were no statistically 
significant differences among the groups.  The results were expressed as mean ± SEM. 
















Figure 3. Disease Index of Smoked and Room Air Animals. Graph showing the 
disease index of both smoked and control animals. Animals treated with smoke and LPS 
had a significantly higher index than those remaining in room air prior to LPS. The 
animals were exposed to either smoke or room air, then given IP LPS 24 hours later. The 
animals were euthanized 24 hours after LPS treatment. The results were expressed as 
mean ± SEM.  Statistical analysis was performed with the two-tailed Mann Whitney test 













Figure 4. Room Air and Smoke Lung Histology. Photomicrograph of paraffin-
embedded sections from hamster lungs stained with hematoxylin and eosin. The left 
photomicrograph represents the lung of an animal exposed to only room air and injected 
with IP LPS. The right photomicrograph represents the lung of an animal exposed to only 
cigarette smoke for 4 hours per day for 3 days. The right photograph shows significantly 
thicker interstitium walls and more infiltrates compared to the left photograph. The 
animals were euthanized 24 hours after IP treatment.  The photomicrographs were taken 













Figure 5. Total amount of Free BALF DID in Smoke and Control. Graph showing the total 
amount of free BALF DID in both Smoked and Control. There was no significant 
difference between the two groups. The animals were exposed to either smoke or room 
air, then treated with IP LPS. There was no statistically significant difference between the 
groups (two-tailed t-test).  The animals were euthanized 24 hours after IP treatment. The 










Figure 6. Total amount of Total BALF DID in Smoke and Control. Graph showing 
the total amount of total BALF DID in both Smoked and Control. There was no 
significant difference between the two groups. The animals were exposed to either smoke 
or room air, then treated with IP LPS. There was no statistically significant difference 
between the groups (two-tailed t-test).  The animals were euthanized 24 hours after IP 
treatment. The results were expressed as mean ± SEM. The numbers under each bar 







Figure 7. Comparison of BALF Free DID and Total DID. Graph showing significant 
correlation between free BALF DID and total BALF DID (r2=0.4728, p<0.01). The 
animals were exposed to either smoke or room air, then treated with IP LPS. The animals 
were euthanized 24 hours after IP treatment. The results were expressed as a simple 
















Figure 8. Linear Regression of Percent Neutrophils and Total BALF DID. Graph 
showing the relationship between Total BALF DID and percent BALF neutrophils. There 
was no significant correlation between these parameters (r2= 0.02, p<0.05) The animals 
were exposed to either smoke or room air, then treated with IP LPS. The results were 
expressed as a simple linear regression at 95% confidence level (N of 19 on both X and Y 













Figure 9. Linear Regression of Percent Neutrophils and Free BALF DID. Graph 
showing the relationship between free BALF DID and percent neutrophils. There was no 
significant correlation between these parameters (r2=0.07, p<0.05).  The animals were exposed to 
either smoke or room air, then treated with IP LPS. The results were expressed as a simple 














3.2 Model 2 – The effect of BQ-123 on smoke-enhanced LPS Inflammation 
 An endothelin receptor inhibitor was utilized to determine the potential role of 
endothelin in smoke-enhanced LPS-induced inflammation. As shown in Figure 11, the 
hamsters were exposed to cigarette smoke for 4 hours per day over a 3-day period, then 
treated with IP BQ123 prior to LPS administration, there was a significant decrease in 
percent BALF neutrophils with animals given BQ123 compared to LPS alone. (8.5 vs 
15.8 percent, respectively, p<0.05). However, there was no significant difference in the 














Figure 10. BALF Leukocytes for Both LPS and BQ123. Graph showing the total 
BALF leukocyte counts. The animals were exposed to smoke and treated 24 hours later 
with either IP LPS or IP BQ-123 and IP LPS 30 minutes later. All animals were 
euthanized 24 hours after IP treatment.  There was no statistically significant difference 
between the groups (two-tailed t-test).  The results were expressed as mean ± SEM. The 















Figure 11. BALF Neutrophils for both LPS and BQ123. Graph showing the percent 
neutrophil content. The animals were exposed to smoke and treated 24 hours later with 
either IP LPS or IP BQ-123 and IP LPS 30 minutes later. All animals were euthanized 24 
hours after IP treatment. There was a statistically significant difference between the 
groups (p<0.05; two-tailed t-test).  The results were expressed as mean ± SEM 














3.3 Model 3 – The effect of ET-1 on smoke-enhanced Inflammation 
 The use of exogenous administration of ET-1 was utilized to show whether ET-1 
can influence the number of neutrophils entering the lungs. The hamsters were exposed to 
cigarette smoke for 4 hours per day over a 3-day period, then the animals were treated 
with IP ET-1. Another group of hamsters was exposed to room air only, then given IP 
ET-1. As shown in Figure 12, total BALF leukocytes were significantly decreased in 
smoke exposed animals receiving ET-1 compared to animals only treated with smoke 
(23.5 vs 60.4 x 104, p<0.01). There was also a significant decrease in BALF leukocytes in 
room air exposed animals given ET-1 compared to those left untreated (26.2 vs 67.0 x 
104, p<0.001). As shown in Figure 13, there was a significant increase in percent 
neutrophils in the room air/ET-1 group compared to room air only controls (12.5 vs 5.2, 
respectively, p<0.01). These findings suggest that ET-1 may preferentially increase 









Figure 12. Total Leukocyte Content for ET-1 with Smoked and Room Air Animals. 
Graph showing BALF leukocyte content. All animals were exposed to cigarette smoke or 
room air prior to the IP injection protocol. The animals were treated with either IP ET-1 
or PBS 24 hours post-smoke exposure and euthanized one day later.  For both smoke and 
room air-exposed animals, ET-1 significantly decreased BALF leukocytes and compared 
using one-way ANOVA with Bonferroni post-test.  The results were expressed as mean ± 
SEM. The numbers under each bar represent the sample size (N). The numbers under 













Figure 13. Percent Neutrophils Content for ET-1 with Smoked and Room Air 
Animals. Graph showing BALF neutrophil content. All animals were exposed to 
cigarette smoke or room air prior to the IP injection protocol. The animals were treated 
with either IP ET-1 or PBS at 24 hours post-smoke exposure and euthanized one day 
later.  Both the smoke + ET-1 and ET-1 only groups had significantly increased BALF 
neutrophils compared to controls exposed to room air and injected with PBS and 
compared using one-way ANOVA with Bonferroni post-test. The results were expressed 












3.4 Model 4 – The effect of ET-1 and BQ-123 on smoke-enhanced LPS Inflammation 
 Both ET-1 and BQ-123 were used to look at their effect on LPS-enhanced 
inflammation in smoke-exposed animals. As shown in Figure 15, there was a significant 
increase in percent BALF neutrophils in the Smoke+LPS group compared to room air 
controls (9.3 vs 1.5 percent, respectively; p<0.01), which was abrogated by both BQ123 
and ET-1. Similarly, as show in Figure 14, there was a significant increase in total BALF 
leukocytes in the Smoke+LPS group compared to room air controls, which was reversed 
with ET-1 and BQ123 (84.40 vs 19.85 vs 25.95 x 104, respectively; p<0.0001).  These 
changes in BALF neutrophil populations are shown in Figure 16.  
 Animals treated with Smoke + LPS and Smoke + LPS + ET-1 had a significantly 
higher disease index than room air controls that were not treated with these agents (1.8 
and 1.9 vs 0.8, respectively; p<0.0001; Figures 17 and 18). These findings suggest that 
ET-1 may cause thickening of the alveolar wall and increases in the disease index, 
despite limiting the influx of leukocytes into the lung.  Such an effect is possible if ET-1 







Figure 14. Total Leukocyte Content for LPS, ET-1 and BQ-123. Graph showing 
BALF leukocyte content. All animals were exposed to cigarette smoke or room air prior, 
then given IP injections of either BQ123 or ET-1 at 24 hours post-smoke exposure. 
Animals receiving BQ123 were first treated with this agent and then given LPS 30 
minutes later. Animals receiving ET-1 were first treated with LPS and then treated with 
ET-1 30 minutes later. All animals were euthanized 24 hours after IP treatment. The 
group receiving smoke + LPS had significantly increased BALF leukocytes compared to 
all other groups using one-way ANOVA with Bonferroni post-test.  The results were 












Figure 15. Percent Neutrophil Content for LPS, ET-1 and BQ123. Graph showing 
BALF neutrophil content. All animals were exposed to cigarette smoke or room air prior, 
then given IP injections of either BQ123 or ET-1 at 24 hours post-smoke exposure. 
Animals receiving BQ123 were first treated with this agent and then given LPS 30 
minutes later. Animals receiving ET-1 were first treated with LPS and then treated with 
ET-1 30 minutes later. All animals were euthanized 24 hours after IP treatment.  The 
group receiving smoke + LPS had significantly increased BALF neutrophils compared to 
the room air + PBS group and compared using one-way ANOVA with Bonferroni post-
test.  The results were expressed as mean ± SEM. The numbers under each bar represent 









Figure 16. BALF Photomicrographs – BQ-123, ET-1, LPS, and PBS. 
Photomicrographs showing neutrophil content with animals exposed to BQ-123, LPS, 
and ET-1 taken at 200x. On the top left, there is significantly less neutrophils when BQ-
123 is used compared to LPS. On the top right, there is significantly less neutrophils 
when ET-1 is used compared to LPS. The groups involving BQ-123, LPS, and ET-1 were 







Figure 17. Disease Index of ET-1, BQ-123, and LPS with Smoked animals. Graph 
showing the disease index of LPS, ET-1+LPS, BQ123+LPS and Room Air+PBS. 
Animals treated with smoke and treated with IP LPS+ET-1 and LPS had a significantly 
higher index than those remaining in room air prior to LPS (p<0.0001).  The animals 
were exposed to either smoke or room air, then given IP LPS 24 hours later. The animals 
were euthanized 24 hours after LPS treatment. Statistical analysis was performed with a 
one-way ANOVA test. The results were expressed as mean ± SEM (p<0.0001). The 













Figure 18. Lung Histology of BQ-123, ET-1, LPS, and PBS Photomicrographs of 
paraffin-embedded slide sections from lungs treated with smoke and injected with either 
ET-1, LPS, or BQ-123.  Controls were exposed to room air and given PBS which had 
thicker interstitial walls and more infiltrates when compared to the control. The 
photomicrograph on the top right shows an animal smoked and treated with LPS + ET-1 
which had thicker walls and more infiltrates when compared to the control. The animals 








3.5 Chemotaxis Assay 
 A Boyden chamber assay was used to measure the chemotactic activity of LPS in 
smoked hamsters. As shown in Figure 19, BALF leukocytes from hamsters exposed to 
smoke and did not show increased chemotaxis for LPS dissolved in culture media 
compared to media alone (72.0 vs 46.8 fluorescence units per 104 cells).  Similarly, 
BALF leukocytes from room air exposed animals showed no enhancement in chemotaxis 
for LPS (83.1 and 39.9 fluorescence units per 104 cells, respectively).  These results 
suggest that the effect of LPS on leukocyte migration into the lung is not directly related 
to the chemotactic activity of LPS but may instead depend on secondary release of 












Figure 19. Chemotaxis Assay. Graph showing the chemotaxis assay results. There was 
no significant difference between the animals exposed to smoke and room air. BALF 
leukocytes from both smoked and room air animals were exposed to LPS in a Boyden 
chamber (chemotaxis) assay. Relative fluorescence emission of leukocytes was measured 
at a fluorescent plate reader using a 480/520 nm filter set. Results were expressed as 
mean ± SEM. Comparison among groups was done using one-way ANOVA followed by 
Bonferroni multiple comparison post-hoc test. The numbers under each bar represent the 












3.6 Mean Linear Intercept 
 Measurement of the Mean Linear Intercept was performed 24 hours after LPS 
treatment to determine whether short-term exposure to cigarette smoke combined with 
secondary inflammation induced by LPS can induce emphysematous changes. As shown 
in Figure 20, animals treated with Smoke+LPS had a significantly greater MLI compared 
to animals treated with room air and PBS (83.60 vs 55.7 respectively; p<0.0001). These 
findings suggest that even brief exposure to second-hand cigarette smoke can result in 














Figure 20. Mean Linear Intercept on Lung Airspace Diameter. Graph showing a 
significant difference in mean linear intercept on the lung airspace diameter. Animals 
treated with Smoke+LPS had a significantly larger airspace compared to animals treated 
with room air and PBS. The first group was exposed to smoke for 4 hours per day during 
a period of 3 days and injected with IP LPS. The second group was only exposed to room 
air and PBS. The animals were then euthanized 24 hours after IP administration. The 













3.7 Free Lung Desmosine 
 Measurements of free lung desmosine were conducted 24 hours after IP LPS 
treatment to determine whether the combination of smoke exposure and secondary 
inflammation can cause increased elastic fiber injury and if this can be a better biomarker 
for elastic fiber damage compared to using free BALF desmosine. As shown in Figure 
21, free lung desmosine was significantly higher in the group exposed to Smoke+LPS 
compared to the other groups treated with smoke only, room air+LPS, and room air only 
(359.1 vs 95.05 vs 93.07 vs 0.000 respectively). This suggests that the combination of 
cigarette smoke and LPS acts synergistically regarding elastic fiber injury and that free 
lung desmosine may be a better indicator of damage to these fibers than free BALF 
desmosine. These results in combination with the MLI measurements support the 
hypothesis that short-term cigarette smoke increases the susceptibility of the lung to 









Figure 21. Free Lung Desmosine. Graph showing significant difference in Free Lung 
Desmosine. Animals treated with Smoke+LPS have a significantly higher amount of free 
desmosine in the lung compared to the Smoke, Room-Air+LPS, and Room air. The 
animals were exposed to either smoke or room air, then given IP LPS or PBS 24 hours 
later. The animals were euthanized 24 hours after treatment. Statistical analysis was 














CHAPTER 4: DISCUSSION 
4.1 Smoke Exposure and Secondhand Smoke Exposure 
 Cigarette smoking and secondhand cigarette smoke exposure continue to be a 
major issue in the U.S. According to the CDC and US Surgeon General, tobacco smoking 
has contributed to more than 480,000 deaths per year in the United States, including more 
than 41,000 deaths resulting from secondhand smoke exposure (United States 
Department of Health and Human Services, 2014). Smoking has been known to cause 
cancer, heart disease, lung diseases, COPD, emphysema, and chronic bronchitis. 
Secondhand smoke has also been a contributing factor in smoke-related deaths as 
secondhand exposure can increase the risk of a stroke. In children, exposure to 
secondhand smoke increases their risk of ear infections, severe asthma attacks, 
respiratory infections, and a greater risk of sudden infant death syndrome. In adults, non-
smokers exposed to secondhand smoke can cause heart disease, lung cancer, and stroke. 
 
4.2 Cigarette Smoke and Bacterial Infections 
 As it is well known that cigarette smoke can cause a variety of issues, bacterial 
infections are one of the most critical problems affecting smokers and nonsmokers. 
Active smokers and those exposed to secondhand smoke are at increased risk of bacterial 
infections. Cigarette smoke exposure increases the susceptibility to respiratory diseases 
and infections in the lung such as tuberculosis and pneumonia. This can cause smokers 
and nonsmokers to be more vulnerable to multiple bacterial infections which can be life-
threatening for both active smokers and nonsmokers. They can be exposed to bacteria 




bacterial infections in both active and second-hand smokers than in nonsmokers. 
Lipopolysaccharides (LPS) are used in our experiments to stimulate bacterial infections 
such as meningococcus due to it being a gram-negative bacterium capable of producing 
endotoxins similar to LPS (Rouphael & Stephens, 2012). Other studies have shown that 
cigarette smoke can drastically increase air concentrations of endotoxins with each 
inhalation containing 17.4 pmol of endotoxin per smoked cigarette (Larsson et al., 2004). 
 
4.3 Management of Smoking and Prevention of Acute Lung Injury 
 With cigarette smoke being a major contributor to deaths in the US, there are 
methods to stop smoking that can decrease your risk of respiratory diseases and bacterial 
infections. The most common is smoking cessation. According to the US Surgeon 
General cessation of cigarette smoking is beneficial at any age as it improves health 
status and enhances the quality of life. It reduces the risk of many adverse health effects 
such as respiratory diseases, COPD, and bacterial infections (United States Department 
of Health and Human Services, 2014). Other methods of smoke cessation have been used 
such as nicotine replacement therapy or smoke cessation medications (Feldman & 
Richards, 2018). There are FDA-approved smoking cessation drugs such as varenicline 
and bupropion to prevent you from continuing smoking. There are also more commercial 
and common products such as nicotine gum and patches. However, there are little to no 
therapeutic agents that have been approved to prevent or reduce acute lung injury. There 
are some methods such as aerosolized high dose systemic corticosteroids that can prevent 
acute lung injury, but it is still under clinical trial and have been associated with worse 





4.4 Current Treatments for Bacterial Infections 
 Since smoking is one of the main risk factors for respiratory diseases, the 
cessation of smoking can decrease the risks of both bacterial infections and respiratory 
diseases such as COPD and emphysema. For the treatment of bacterial infections, the use 
of antibiotics and sometimes antifungal drugs are used. An example would be the use of 
macrolide or tetracycline have been recommended for patients with no risk factors for 
drug-resistant Streptococcus pneumoniae (Feldman & Richards, 2018). Bacterial 
meningitis is a common infection in both smokers and second-hand smokers with a two-
to-fourfold higher risk of getting the infection. The standard treatment for meningitis is 
ampicillin as smokers and secondhand smokers are considered immunocompromised by 
the CDC (United States Department of Health and Human Services, 2014).  
 
4.5 LPS Causes Sequestration of Neutrophils in the Alveolar Wall Capillaries 
 Secondhand smoke exposure is well known to cause inflammation in the lungs. 
Our results have shown that secondhand smoke exposure and intraperitoneal injection of 
LPS causes an increased number of neutrophils in the lungs and increased thickness in 
the alveolar walls. In addition, LPS-treated lung tissue saw an increased movement of 
neutrophils into the alveolar wall, causing accumulation in the interstitium and alveolar 
walls (Figure 4). Other studies have shown that cigarette smoke exposure causes 
polymorphonuclear leukocytes, causes an increased number of PMN in the circulation, 
and a degree of deterioration in lung function. This type of accumulation can be caused 
by the deformability of PMN following smoke exposure which may be a cause in their 




 In our histology, we saw that LPS can cause diapedesis of the sequestered 
neutrophils which then accumulate in the alveoli, contributing to the increased 
inflammation and thickness of the interstitium (Figure 4). Animals treated with cigarette 
smoke and LPS had a significantly higher disease index compared to the control (Figure 
3). There were significantly more infiltrates and thicker interstitium walls indicating that 
both cigarette smoke and LPS increased inflammation in the alveolar walls. This occurs 
when the inflammatory response goes through a process of reaching the site of 
inflammation and moves through the endothelial surface towards the tissue. The 
infiltration of activated neutrophils into the lung compartments is one of the indicators in 
acute lung injury and acute respiratory distress syndrome. Cigarette smoke has been 
known to be associated with an increased incidence of acute respiratory distress 
syndrome (Siew et al., 2016). Other studies have shown that the administration of 
aerosolized LPS can cause LPS-induced PMN transendothelial migration into the 
interstitial space and alveolar airspace. (Basit et al., 2021).  
 
4.6 Use of Endothelin Receptor Antagonists and Blockage of Endothelin Receptors 
 Endothelin Receptor antagonists (ERAs) play an important role in the treatment 
of pulmonary arterial hypertension and have been tested for their protective effects in 
different models of acute lung injury (ALI). Our laboratory and other studies have used 
ERAs to prevent the development of ALI and ET-1-induced lung edema. In previous 
laboratory experiments, Patel et al used a novel endothelin antagonist called HJP272 
which resulted in attenuated LPS-induced acute lung injury in hamsters in which HJP272 




studies have used nonselective ERAs such as Bosentan and Tezosentan. Chen et al have 
used bosentan and other ERAs in determining that ET-1 plays an important role in the 
pathogenesis of emphysema. The use of bosentan and BQ123 prevented the development 
of cigarette smoke extract-induced emphysema and blocked the expression of the ETA 
receptor (Chen et al., 2010). 
In our results, we have shown that blocking endogenous ET-1 may counteract the 
effects of LPS in the alveolar and inflammatory response with the use of ERAs. In Figure 
11, there was a significant decrease in neutrophil content in the group treated with BQ123 
compared to a group treated without BQ123. It is also shown in Figure 11 and 15, there 
was a significant decrease of neutrophils in a group injected with BQ123 compared to a 
group treated only with smoke+LPS. Since BQ-123 is known to be a selective antagonist 
for the ETA receptor and can competitively block the receptor, reducing the likelihood of 
ET-1 from binding. It is possible that when BQ-123 blocks ETA receptors which 
prevents endogenous ET-1 from binding to the receptors which reduce the level of 
inflammatory response against LPS and resulting in lower neutrophil counts compared to 
the animals treated with LPS or cigarette smoke. Other studies have shown that BQ-123 
has protective effects against LPS-induced oxidative stress in the Wistar rat lungs and 
concluded that BQ-123 was able to prevent lung edema development and decrease LPS-
induced oxidative stress (Piechota et al., 2011). Another study conducted by Sampaio et 
al showed that intratracheal instillation of BQ-123 inhibits neutrophil and eosinophil 
accumulation in LPS-induced pleurisy (Sampaio et al., 2004). 
 




 Our results have shown that external use of ET-1 can cause neutrophils to migrate 
towards the lung and sequester into the alveolar walls in animals not treated with either 
LPS or smoke. As shown in Figure 12, there was a significantly higher number of 
leukocytes in the smoke and room air compared to animals treated with Smoke+ET-1 and 
Room Air+ET-1. This indicates that there are possible vasoconstrictions on the airways 
and parenchyma that reduce the number of leukocytes entering the lung. A study done by 
Admaicaza et al showed that the use of exogenous ET-1 can induce significant changes in 
the mechanical properties of the airways and parenchyma in guinea-pig lungs (Adamicza 
et al., 2001). In Figure 13, there was a significant increase in neutrophils in groups treated 
with ET-1 and cigarette smoke compared to animals exposed to room air and smoke+ET-
1. This may be due to the fact that many endothelial cells produce endogenous ET-1 
which includes leukocytes and macrophages (Kowalczyk et al., 2015). ET-1 also 
stimulates the synthesis of TNF-α which further enhances the inflammatory response by 
stimulating the chemotaxis and phagocytosis of macrophages, monocytes, and 
neutrophils.  It is possible that the exogenous ET-1 may cause the neutrophils to 
sequester into the lungs due to it being attracted to ET-1 as it is a proinflammatory 
mediator. Other studies have shown that ET-1 induces neutrophil recruitment in adaptive 
inflammation via TNAF-𝞪 and CXCL1/CXCR2 in mice (Zarpelon et al., 2012). 
 
4.8 Exogenous ET-1 may cause vasoconstriction in smoked-induced and LPS-
induced, reducing the effects of neutrophil diapedesis. 
 Exogenous ET-1 may cause vasoconstriction in smoked-treated animals. Cigarette 




increased endogenous ET-1 from cigarette smoke exposure. Cigarette smoke can induce 
ET-1 synthesis to respond to the smoke-induced inflammation. As shown in Figure 15, 
there was a significant increase of neutrophil content in animals treated with smoke+LPS 
compared to the group treated with smoke+LPS+ET-1. It is possible that adding 
exogenous ET-1 to already existing endogenous ET-1 may cause the blood vessels to 
constrict further towards the lungs, resulting in fewer neutrophils in the alveoli. Other 
studies have shown that ET-1 levels are elevated in heavy and light smokers and patients 
who have COPD and pulmonary hypertension (Lu et al., 2018). They also have shown 
that cigarette smoke also elevates ET-1 levels and causes increased expression of ETA 
receptors (Milara et al., 2012). With cigarette smoke already increasing the levels of 
endogenous ET-1, an additional amount of exogenous ET-1 entering the body can cause 
an increased effect on vasoconstricting which can decrease the number of neutrophils 
entering the lung.  
 
4.9 Exogenous ET-1 may reverse LPS-induced vasodilation, counteracting its effect 
on neutrophil diapedesis. 
 Exogenous ET-1 may reverse LPS-induced vasodilation in the alveolar walls 
which can counteract the effects of neutrophils diapedesis. LPS is known to cause 
vasodilation when injected into animals, which increases the inflammatory response of 
neutrophils (Farias et al., 2002). Our results have shown that when the animals were 
exposed to cigarette smoke and then injected with LPS it increased the number of 
leukocytes and neutrophils entering the lung compared to a group treated with 




Smoke+LPS animals were injected with IP exogenous ET-1, the number of leukocytes 
and neutrophils significantly decreased compared to the group treated with smoke and 
LPS. It is possible that the ET-1 is constricting the blood vessels that are already dilated 
from the endotoxin, reducing neutrophil diapedesis. Our results have also indicated that 
there is rapid neutrophil turnover in the lungs as the exogenous ET-1 has a vasopressor 
effect on the BALF neutrophil counts by lowering the cumulative positive effect of 
smoke exposure (Figure 15). It is possible that there are a lower number of BALF 
neutrophils due to exogenous ET-1 inducing vasoconstriction in the blood vessels, 
resulting in fewer neutrophils in smoke-treated animals. However, the mechanism on 
how ET-1 can reverse LPS-induced vasodilation in the alveolar walls is uncertain. 
 
4.10 Short-term Smoke Exposure and Elastin Breakdown 
 Short-term exposure to second-hand cigarette smoke increased the number of lung 
neutrophils but it was not enough to cause significant elastin breakdown. Desmosine and 
isodesmosine are used as a biomarker for elastin breakdown and are found in different 
matrices such as the lung and the sputum (Luisetti et al., 2008). Our results have shown 
that animals exposed for 4 hours daily for a period of 3 days had an increased number of 
neutrophils and leukocytes in the lung but there was no significant correlation in elastin 
breakdown and percent neutrophils in the BALF. However, there was a correlation 
between the free BALF desmosine and total BALF desmosine levels (Figure 7).  
As shown in Figure 20, the lung airspace size was measured, and it showed a 
significant increase in airspace size compared to the control group. This is consistent with 




lung desmosine is a better indicator of lung damage compared to BALF desmosine. In the 
group exposed to Smoke+LPS (Fig.21), there was a significantly higher amount of free 
desmosine compared to the other groups. This may indicate that the combination of short-
term cigarette smoke and secondary inflammation caused by LPS may cause significant 
elastin damage in the lung. Cigarette smoke and LPS appear to interact synergistically 
which can result in more damage to the lung. This type of result is similar to patients 
diagnosed with emphysema and a common feature of COPD (Wollmer et al., 2014). Our 
laboratory has previously shown that smoke-induced elastin breakdown may take 1 to 2 
months of exposure. When the animals were exposed to cigarette smoke for 3 months, the 
percent lung surface area decreased and the amount of free BALF desmosine increase 
significantly during the second month of exposure (Cantor et al., 2018). Other studies 
have shown that desmosine can be a reliable biomarker for COPD and pulmonary 
emphysema that can be found in urine, plasma, sputum, lung, and BALF matrices. 
(Luisetti et al., 2008) (Cantor et al., 2018) 
 
4.11 Conclusion 
 The results obtained from the cigarette smoke/LPS model suggest that many 
secondhand smokers can become increasingly vulnerable to secondary infections that 
cause more damage to their lungs. Our results show that acute exposure to cigarette 
smoke and simulating a secondary infection using LPS causes enlargement of airspace 
size that is irreversible due to elastic fiber degradation and rupture of alveolar walls. The 
use of endothelin receptor antagonist may help decrease the inflammatory response and 
possibly prevent further acute lung injury, based on our finding that BQ-123, a potent 




increased the proportion of BALF neutrophils in animals exposed to room air while 
lowering total BALF leukocyte content, consistent with its previously demonstrated 
proinflammatory effect on neutrophils.  However, in animals pretreated with both smoke 
and LPS, exogenous ET-1 showed anti-inflammatory activity, suggesting the possibility 
that its vasopressor effect on the capillary bed compromises blood flow to the lung, 
thereby reducing leukocyte influx into the lung.  Further investigation of the effects of 
ET-1, bacterial infections, and ERAs on smoke-related lung injury may lead to more 
effective approaches to preventing exacerbation of elastic fiber damage and 
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